NCT07306598 [18F]NIDF PET Imaging in Tau-related Diseases
| NCT ID | NCT07306598 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tianjin Medical University |
| Condition | Neurodegenerative Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-11-01 |
| Primary Completion | 2030-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2025-11-01 with a primary completion date of 2030-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In the field of diagnosing brain neurodegenerative diseases, it is now a well-established practice to inject positron-emitting tracers into the human body. These tracers bind to specific target proteins, allowing their distribution to be visualized via PET imaging. Currently, several research groups worldwide are engaged in developing and clinically validating their own tau imaging agents. This clinical research project aims to visualize abnormal tau pathology in the living human brain using \[18F\]NIDF PET imaging. \[18F\]NIDF is a 2-arene-azaindole-based tracer that offers stronger binding affinity to tau neurofibrillary tangles and reduced non-specific/off-target binding compared to existing tau-PET imaging agents. The study primarily focuses on evaluating the safety and diagnostic efficacy of \[18F\]NIDF PET imaging in human subjects.
Eligibility Criteria
Inclusion Criteria: 1. Between 18 and 90 years old; 2. No gender limitation; 3. Clinical diagnositic rerults supported the diagnosis of neurodegeneration, and there was no evidence of other neurological diseases; 4. Healthy participants or patients with probable Alzheimer's disease or with dementia due to other causes; 5. Informed consent signed in person by the subject or his legal guardian or caregiver. Exclusion Criteria: 1. Has allergy to \[18F\]NIDF or any of its excipients; 2. Incapable of providing written informed consent or lacking a legally authorized representative (LAR) to provide informed consent ; 3. Unwilling or unable to undergo PET scans tracer injections; 4. Any condition that, in the Investigator's opinion, could increase the risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection/analysis of the data (e.g., renal or liver failure, advanced cancer); 5. Received an experimental drug or device within 1 month (whose efficacy or safety is unclear); 6. Have other serious neurological disorders, or gastrointestinal, cardiovascular, liver, kidney, blood system, tumor, endocrine, respiratory, immune deficiency, and other serious diseases; 7. Women who are currently pregnant or breastfeeding.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07306598 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Neurodegenerative Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07306598 currently recruiting?
Yes, NCT07306598 is actively recruiting participants. Contact the research team at macrossplusvoices@163.com for enrollment information.
Where is the NCT07306598 trial being conducted?
This trial is being conducted at Hefei, China, Tianjin, China.
Who is sponsoring the NCT07306598 clinical trial?
NCT07306598 is sponsored by Tianjin Medical University. The trial plans to enroll 20 participants.